Pharming Group N.V. 

$11.48
424
-$0.22-1.88% Monday 20:00

Statistics

Day High
11.66
Day Low
11.48
52W High
21.34
52W Low
9.62
Volume
12,356
Avg. Volume
13,158
Mkt Cap
812.53M
P/E Ratio
72.95
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.02
-0.01
0
0.01
Expected EPS
0.01115
Actual EPS
N/A

Financials

0.67%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
376.13MRevenue
2.54MNet Income

Analyst Ratings

38.67Average Price Target
The highest estimate is 41.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHAR. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Carlisle Companies
CSL
Mkt Cap14.16B
CSL Behring competes in the plasma-derived and recombinant therapeutic products space, similar to Pharming's focus on protein replacement therapies.
Takeda Pharmaceutical
TAK
Mkt Cap57.58B
Takeda Pharmaceutical Company has a strong presence in the rare diseases market, directly competing with Pharming's portfolio.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing with Pharming's approach to treatment.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in the treatment of cystic fibrosis and other rare diseases, presenting competition in the rare disease market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen operates in the biotechnology field focusing on rare diseases among other areas, making it a competitor in the biopharmaceutical market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in developing and marketing products for rare diseases, among other areas, competing with Pharming.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a diverse portfolio including treatments for rare diseases, competing with Pharming in various therapeutic areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the pharmaceutical and biotech industry.
Sanofi
SNY
Mkt Cap107.39B
Sanofi focuses on rare diseases, multiple sclerosis, and oncology, among others, competing with Pharming in the rare disease space.

About

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Show more...
CEO
Fabrice Chouraqui
Employees
409
Country
Netherlands
ISIN
US71716E1055
WKN
000A2QLQY

Listings

0 Comments

Share your thoughts

FAQ

What is Pharming Group N.V. stock price today?
The current price of PHAR is $11.48 USD — it has decreased by -1.88% in the past 24 hours. Watch Pharming Group N.V. stock price performance more closely on the chart.
What is Pharming Group N.V. stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Pharming Group N.V. stocks are traded under the ticker PHAR.
Is Pharming Group N.V. stock price growing?
PHAR stock has fallen by -2.46% compared to the previous week, the month change is a +13.89% rise, over the last year Pharming Group N.V. has showed a -22.93% decrease.
What is Pharming Group N.V. market cap?
Today Pharming Group N.V. has the market capitalization of 812.53M
When is the next Pharming Group N.V. earnings date?
Pharming Group N.V. is going to release the next earnings report on November 05, 2026.
What were Pharming Group N.V. earnings last quarter?
PHAR earnings for the last quarter are 0 USD per share, whereas the estimation was 0.01 USD resulting in a -68.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pharming Group N.V. revenue for the last year?
Pharming Group N.V. revenue for the last year amounts to 376.13M USD.
What is Pharming Group N.V. net income for the last year?
PHAR net income for the last year is 2.54M USD.
How many employees does Pharming Group N.V. have?
As of September 01, 2026, the company has 409 employees.
In which sector is Pharming Group N.V. located?
Pharming Group N.V. operates in the Health & Wellness sector.
When did Pharming Group N.V. complete a stock split?
The last stock split for Pharming Group N.V. was on October 15, 2013 with a ratio of 1:1000.
Where is Pharming Group N.V. headquartered?
Pharming Group N.V. is headquartered in Leiden, Netherlands.